Scope, Claims, and US Patent Landscape for US Drug Patent 6,479,535
US Patent 6,479,535 claims a fixed combination of (1) a specific indole derivative and (2) conjugated estrogens, with therapeutic uses centered on vasomotor symptoms and bone protection in postmenopausal or estrogen-deficient women. The independent claim set is tightly structured: composition claim (claim 1) and method claims (claims 2, 4, 5) that are use-limited to postmenopausal estrogen-deficient populations and clinical endpoints (hot flushes and osteoporosis/bone demineralization). Dependent claim 3 narrows vasomotor symptoms to hot flushes.
What is the protected subject matter in US 6,479,535?
Claim 1: What composition is covered?
Scope: A pharmaceutical composition that contains:
- Active A: 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol (or a pharmaceutically acceptable salt)
- Active B: conjugated estrogens
- Each in a pharmaceutically effective amount
Practical coverage boundaries:
- A product falls within claim 1 only if it includes both Active A and conjugated estrogens.
- “Conjugated estrogens” is a category term and typically maps to commercial conjugated estrogen preparations, not “any estrogen.” The claim does not say “estradiol” or “any estrogenic compound.”
- The indole derivative must be the specified chemical entity (or salt). Different stereoisomers, analogs, or close structural variants are not automatically within scope unless they meet literal identity or a doctrine-of-equivalents theory (not assessed here).
Claims 2 and 3: What medical use is covered?
Claim 2 covers a method for:
- Treating vasomotor symptoms in a postmenopausal or estrogen-deficient woman
- By administering “an effective amount” of the combination of Active A + conjugated estrogens
Claim 3 narrows claim 2:
- Vasomotor symptom = hot flushes
Coverage logic:
- The method is use-limited to vasomotor symptom treatment.
- The patient population is limited to postmenopausal or estrogen-deficient women.
- It requires administering the combination (not Active A alone and not conjugated estrogens alone).
Claim 4: What bone-related use is covered?
Claim 4 covers:
- Inhibiting or retarding bone demineralization, or
- Treating or inhibiting osteoporosis
- In a postmenopausal or estrogen-deficient woman
- By administering the combination of Active A + conjugated estrogens
Key scope effect: It expands beyond vasomotor symptoms to skeletal outcomes, while preserving:
- same patient population constraint
- same combination constraint
Claim 5: What broader menopausal disorder use is covered?
Claim 5 covers:
- Treating or inhibiting menopausal or postmenopausal disorders
- In a postmenopausal or estrogen-deficient woman
- Via administration of the combination of Active A + conjugated estrogens
Scope risk/clarity issue: “Menopausal or postmenopausal disorders” is broader than claims 2-4. If “vasomotor symptoms” and “osteoporosis” are specific subsets, claim 5 can be argued as covering additional disorder categories, provided they are within the claimed group and supported by the specification.
How narrow is the claim scope in practice?
Narrow elements (hard limitations)
- Exact indole derivative identity: 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol (or salts).
- Exact estrogen category: “conjugated estrogens.”
- Combination requirement: both actives must be present/used in the same administered combination.
- Population: postmenopausal or estrogen-deficient women.
- Use-limited outcomes:
- claim 2/3: vasomotor symptoms, hot flushes
- claim 4: bone demineralization/osteoporosis
- claim 5: menopausal/postmenopausal disorders (broad)
Potentially broader elements (interpretation matters)
- “Pharmaceutically acceptable salt”: can broaden coverage if salts are defined in the specification and used in products.
- “Pharmaceutically effective amount”: allows a wide range of dosing as long as efficacy is claimed/claimed as “effective.”
What does the claim set imply for competitive freedom-to-operate?
If a competitor uses Active A + a different estrogen
- Substitution of conjugated estrogens with estradiol or another estrogenic agent should fall outside literal scope of claim 1 and the method claims, because the claim says “conjugated estrogens,” not “estrogens” generally.
If a competitor uses the same estrogen but different indole derivative
- Substitution of Active A with an analog not literally identical to the claimed indole derivative should not satisfy claim 1’s chemical definition, unless equivalency is argued.
If a competitor treats the same patient population but with different indications
- Treatment of vasomotor symptoms in postmenopausal women using Active A + conjugated estrogens is within claims 2 and 3.
- Treatment targeting bone density using Active A + conjugated estrogens is within claim 4.
- Treatment of a menopausal/postmenopausal disorder outside these specific endpoints could still be within claim 5 if it is characterized as a menopausal/postmenopausal disorder.
If a competitor separates actives temporally (non-combination)
- The claims require administering “a combination.” If a party uses the same two actives but not in a “combination” sense, claim coverage becomes fact- and claim-construction-dependent (not resolved here). For product strategy, the safest read for potential risk is to assume the patent targets coformulated or coordinated dosing regimens.
Claim-by-claim scope map (quick reference)
| Claim |
Type |
What is required |
Key limitations |
Main clinical endpoints |
| 1 |
Composition |
Active A (exact indole or salt) + conjugated estrogens |
Both actives; pharmaceutically effective amounts |
Enables the listed indications through composition |
| 2 |
Method |
Administer combination to postmenopausal/estrogen-deficient woman |
Vasomotor symptoms |
Vasomotor symptoms |
| 3 |
Dependent |
Hot flushes |
Narrows claim 2 symptom |
Hot flushes |
| 4 |
Method |
Administer combination to postmenopausal/estrogen-deficient woman |
Bone demineralization/osteoporosis |
Bone demineralization; osteoporosis |
| 5 |
Method |
Administer combination to postmenopausal/estrogen-deficient woman |
General menopausal/postmenopausal disorders |
Broad disorder set |
Patent landscape: what to look for around US 6,479,535
1) Relationship to other claims in the same family
US 6,479,535 is a combination and use patent. In most such programs, common family members include:
- composition coverage variants (salts, dosage forms)
- use coverage (additional menopausal symptoms)
- process or intermediate patents that protect manufacture of the Active A indole derivative
- estrogen formulation patents (if co-administered as a fixed-dose product)
- subpopulation or dosing regimen patents (induction/maintenance schedules)
For competitive analysis, the highest-value landscape queries are:
- family continuations/divisionals that add additional method claims
- later-expiring claims that survive despite amendment
- patents that cover reformulation (tablet, capsule, transdermal) or delivery systems for the combination
2) Landscape against existing hormonal therapy intellectual property
Conjugated estrogens have extensive historical coverage. This matters because a new patent that claims a combination must usually rely on:
- a novel co-therapeutic agent (Active A) and/or
- a particular use claim that is not fully anticipated by earlier estrogen-only methods
Your claim set explicitly requires the novel indole derivative plus conjugated estrogens, so older conjugated estrogen method patents generally do not read directly onto infringement unless they already teach or claim the exact combination.
3) Likely relevant third-party patent clusters
Even without enumerating each document here, the competitive space typically contains these clusters:
- indole-derivative SERM/SERD/estrogen-modulating analog patents (Active A chemical class)
- combination-use patents for menopausal symptoms using non-estrogen agents plus hormone replacement
- osteoporosis/bone-sparing treatment patents involving estrogen and non-estrogen co-therapies
- combination product form patents (dose ratios, formulations)
4) Expiration and regulatory linkage considerations (how to time risk)
For combination products, the binding question for market exposure risk usually turns on:
- patent expiry dates for the combination claims (composition and method)
- whether any later patents in the same family extend exclusivity through continuation
- whether the compound indole derivative has separate earlier-later filings that change overall expiry sequencing
- regulatory exclusivity drivers (where applicable) that can keep competition away even if some claims expire
Actionable insight: For launch planning, treat US 6,479,535 as a “safety barrier” for any product that includes the exact indole derivative plus conjugated estrogens aimed at vasomotor and bone endpoints in postmenopausal women.
Built-in enforceability hooks inside the claim wording
Combination is the enforcement anchor
All independent and dependent method claims require the combination of Active A + conjugated estrogens. This is the central enforceability hook.
Population limitation is an infringement filter
All method claims require postmenopausal or estrogen-deficient women. If a competitor markets for different patient populations, they may argue non-infringement (or carveouts), though labeling and real-world use can blur this.
Symptom-specific dependent claim reduces ambiguity
Claim 3 fixes “hot flushes.” That narrows the symptom mapping and can reduce disputes over whether a given study or clinical endpoint qualifies as vasomotor symptom treatment.
Key Takeaways
- US 6,479,535 protects a fixed combination: 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol (or salt) plus conjugated estrogens.
- The claim set covers composition (claim 1) and methods for:
- vasomotor symptoms in postmenopausal/estrogen-deficient women (claims 2 and 3, with hot flushes specified)
- bone demineralization/osteoporosis (claim 4)
- broader menopausal/postmenopausal disorders (claim 5)
- The core risk for competitors is formulation or regimen decisions: using the same indole derivative with conjugated estrogens to treat these endpoints is the direct infringement path.
- The main design-around levers are structural and categorical: change the indole derivative or change the estrogen category (from conjugated estrogens to another estrogen), and avoid the claimed use population and outcomes.
FAQs
1) Does the patent cover Active A with estrogen if the estrogen is not conjugated estrogens?
No, the claims specify “conjugated estrogens.” A different estrogen category is outside the literal claim language.
2) Are vasomotor symptoms and hot flushes both covered?
Yes. Claim 2 covers vasomotor symptoms, and claim 3 narrows to hot flushes.
3) Can a product infringe if it targets osteoporosis but not vasomotor symptoms?
Yes. Claim 4 independently covers osteoporosis/bone demineralization treatment with the combination.
4) Does the composition claim require a specific dosage form (tablet, capsule, etc.)?
Claim 1 is a pharmaceutical composition claim but does not, on the claim text provided, require a specific dosage form beyond containing the required actives in effective amounts.
5) Is “menopausal or postmenopausal disorders” limited to osteoporosis and vasomotor symptoms?
The term in claim 5 is broader than claims 2-4, so it can cover other menopausal/postmenopausal disorders if they fall within that category and the combination is administered to the claimed population.
References
- United States Patent 6,479,535.
